Navigation Links
Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR
Date:10/8/2008

nue opportunity; that Poly-ICR will not be useful in the treatment of GW or actinic keratosis; that we will not complete development activities or file an IND application in connection with Poly-ICR; that we will not finalize manufacturing or formulation protocols or file an IND in connection with Hsp 6/11; that we will be unable to execute our corporate restructuring as planned; that we will be unable to expand corporate development efforts as planned and that such efforts will not produce the desired results; that results from future clinical trials will not be consistent with our expectations; that we will not be able to recruit patients for our planned trials in a timely manner; our need for capital, which may not be available on a timely basis, or at all; risks associated with requirements for approvals by government agencies such as the FDA before products can be tested in clinical trials; the possibility that such government agency approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to advance development; risks associated with the requirement that a drug candidate be found safe and effective after extensive clinical trials; our dependence on suppliers, collaborative partners and other third parties and the prospects and timing for obtaining clinical supply materials; our ability to attract and retain key personnel; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at http://www.sedar.com.

Assumptions underlying our expectations regarding forward-looking statements or information contained in this press release include, among others that our planned corporate restructuring will have the anticipated affect; that we will succeed in forming strategic alliances and that such alliances will allow us to realize the greatest value for our programs; that we will commence Phase 2 clin
'/>"/>

SOURCE Nventa Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. Nventa Appoints Gordon H. Busenbark to Board of Directors
10. CardioDynamics Provides 2007 Shareholder Meeting Update
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... A mechanised blue dye test alter...ckaging quality assurance one step closer for phar... leak testing machine developed by Sepha for u...alled in several local and global pharma-companies...s quality assurance and productivity improvements ...
(Date:11/25/2009)... ,, BOCARATON,Fla.,Nov.25/PRNewswire/--Formany...icMD.Thenation,slargestandfastestgrowingnetworkofe...upervised bioidenticalhormones has grownthenumbero...m21to36physicians -andisinprogresstoaddmorephysici...fthisyear. ,, Inthepastyear ,BodyLogicMDhasopen...
(Date:11/24/2009)...elease is available in German . , Whether i...ds: RFID tags (Radio Frequency Identification) are.... They make it possible to label objects or goods .... The appropriate scanner can read and process the...affixed to goods under production conditions of up...
(Date:11/24/2009)...ALGARYandBLENHEIM,Ontario,Nov.24/PRNewswire-FirstC...ringtheassetsofHylandSeeds,adivisionofThompsonsLim...lfurtherexpandDowAgroSciences,currentseedsbusiness...(TM) in 2010 andDowAgroSciencesHerbicideTolerant...sexpectedinthenearfuture. ,, "Thisacquisitionbr...
Breaking Biology Technology:Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 2Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 3Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 2Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 3Intelligence inside metal components 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3
...USTIN, Calif., Feb. 12 Peregrine,Pharmaceuticals,...ceutical,company developing targeted therapies for...ection (HCV), today announced that patient dosing ...te the safety and efficacy of,bavituximab in combi...,breast cancer. The primary objective of the study...
...LAREMONT, Calif., Feb. 12 Keck Graduate Institute...dent and CEO of the,Biotechnology Industry Organiz...e System & the Presidential Race: Who Will Regulat...o Distinguished Lecture Series on,Wednesday, March... that Jim Greenwood will serve as our guest,speake...
...ecent Product Introductions Drive 49% Revenue Grow... 66%, WESTFORD, Mass., Feb. 12 Cynosure, In...acturer of a broad array of,light-based aesthetic ...,and net income for the quarter and year ended Dec...sults, Revenues increased 49% to $36.6 million in...
Other Biology Technology:Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer 2Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer 3Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer 4KGI Announces BIO President Greenwood to Address Health Care Reform and the Presidential Race at Simon Ramo Lecture 2KGI Announces BIO President Greenwood to Address Health Care Reform and the Presidential Race at Simon Ramo Lecture 3Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007 2Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007 3Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007 4Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007 5Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007 6Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007 7Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007 8Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007 9Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007 10Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007 11Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007 12
(Date:11/25/2009)...vital to your health as what you eat, found resear.... Their experiments in mice revealed that the dail...iverthe body,s metabolic clearinghouseis mostly co...adian clock as conventional wisdom had it. , "I...number of genes completely independent of the circ...
(Date:11/24/2009)...amed 12 new grant recipients for 2009. The awards,...across a broad spectrum of lupus research. All wer...ntial to drive scientific discovery to ultimately ...stemic lupus. , The 2009 grants go to both new a... and include interdisciplinary and highly promisin...
(Date:11/24/2009)...t may help gut bacteria bind to the gastrointestin...roducers to identify strains that are likely to be... interact with cells lining the gut to have a bene...he gut they are more likely to stick around long e...uge from the Institute of Food Research. IFR is a...
Breaking Biology News(10 mins):Feeding the clock 2Feeding the clock 3Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3A sticky solution for identifying effective probiotics 2Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 1Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 2Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 3Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 4Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 5Winner Medical One for Two Reverse Stock Split Becomes Effective and Begins Trading Under New Symbol 3A WWIN 58965 1Winner Medical One for Two Reverse Stock Split Becomes Effective and Begins Trading Under New Symbol 3A WWIN 58965 2Blue Cross and Blue Shield Companies Honored for Innovative Programs That Help Consumers Live Healthier Lives 58963 1Blue Cross and Blue Shield Companies Honored for Innovative Programs That Help Consumers Live Healthier Lives 58963 2
...sease and drug addiction are polar opposite diseas...rkinson,s patients don,t have enough of it; drug a... of dopamine in these disorders has been well know...earch from Northwestern University,s Feinberg Scho...ens and weakens the two primary circuits in the br...
...who has ever tried smoking probably remembers that...ave of nausea or a nasty coughing fit. For others,...re or "buzz." , Now, a new study links those firs...t a person is currently a smoker, to a particular ...e path that leads from that first cigarette to lif...
...n Beijing kicks off this week, the event is giving...serve how the atmosphere responds when a heavily p...trial emissions. , The National Science Foundatio..." (CAPMEX) will include a series of flights by spe...ous unmanned aerial vehicles (AUAVs). , The aeri...
Other Biology News:Unlocking mystery of why dopamine freezes Parkinson's patients 2Unlocking mystery of why dopamine freezes Parkinson's patients 3If your first cigarette gave you a buzz and you now smoke, a gene may be to blame 2If your first cigarette gave you a buzz and you now smoke, a gene may be to blame 3Scientists to assess Beijing Olympics air pollution control efforts 2Scientists to assess Beijing Olympics air pollution control efforts 3
Rat Albumin EIA Kit from Cayman Chemical
...s at the 3, 3', 4, and 4' positions. It is intende...cation of Prostaglandin E2 (PGE2) by GC- or LC-mas...ygenase products of arachidonic acid and one of th...ivity influences inflammation, fertility and partu...
Agarose Gel Loading Dye Mixture 6X (with ficoll) from GenScript Corporation
Site-directed DNA Mutagenesis Service from Yorkshire Bioscience Ltd
Biology Products: